Small and medium-sized drug dealers will withdraw.

Earlier, the head of the Shanghai Joint Administration of Medicines in the national organization of drug collection press conference made it clear that through regional linkage, to promote the scale, intensive and modernization of drug distribution enterprises.
Indeed, after the results of the third batch of state-organized drug collection and selection were announced, Shanghai Sunshine Pharmaceutical Procurement Network released the third batch of state-harvested Shanghai regional distribution enterprises, from the public list, the third batch of state-organized Shanghai area distribution rights mainly by the drug and state-controlled division, has been difficult to find the figure of small and medium-sized distribution enterprises.
in the first round of 4-7, the distribution of selected drugs in Shanghai is also by the two major pharmaceutical commercial companies of national medicine, medicine.
the reason why in the centralized procurement of drugs organized by the state, distribution enterprises mainly to head drug dealers, mainly because of the high requirements for distribution enterprises.
(1) designated distribution enterprises in 2020 distribution of drugs covering all areas of the city; (2) Designated distribution enterprises have the ability and conditions to distribute selected drugs to the city's medical insurance designated medical institutions within 24 hours.
The above conditions almost determine that only the pharmaceutical circulation field of the head enterprises can eat the national collection of this part of the market - in addition to the high demand for distribution range and distribution speed, the collection of selected drugs significantly reduced prices, the cost control capacity of pharmaceutical distribution enterprises also put forward considerable challenges, for large-scale, intensive pharmaceutical commercial enterprises, under the established channels, the more enterprises distribution products can dilute channel costs.
specifically, in addition to the Shanghai area, other areas with volume procurement of selected drug distribution also presents a head drug manufacturers occupy the main advantage of the situation.
with the normalization of the national organization of drug collection, collection in varieties, categories of continuous expansion, along with the pressure is a large number of small and medium-sized pharmaceutical distributors.
it is also important to see that even pharmaceutical commercial enterprises that have obtained the right to distribute the national varieties are generally faced with increased business and no increase in profits.
Cheng Junpe, vice president of the China Pharmaceutical Business Association, said that China's drug circulation reached 236.67 billion yuan in 2019, up 8.6% year-on-year, showing single-digit growth for the third consecutive year, and the value added of the entire drug circulation market is expected to be around 4% by 2020.
Pharma circulation enterprises generally face development challenges" In recent years, in the two-vote system, the national centralized volume procurement, prescription outflow, e-commerce giants, such as strong intervention in the background, the profit margins of the drug circulation link has been greatly squeezed, the development of many pharmaceutical circulation enterprises are facing unprecedented challenges," a business person said at the meeting.
Before the state organized the collection of medicines, the policy that had the greatest impact on the field of pharmaceutical circulation was the two-vote system, which had a significant expansion effect on the scale of the business of pharmaceutical circulation leaders during the two-vote period, as a result of regulating the distribution relationship between distribution enterprises and hospitals everywhere.
related people said that after the implementation of the two-vote system for some time, the concentration of pharmaceutical circulation has steadily increased, the top five pharmaceutical circulation enterprises market share has reached 40%, 4 percentage points higher than before the two-vote system.
On February 9, 2017, the State Council issued "Several Opinions on Further Reforming and Perfecting the Policy on the Production and Circulation of Pharmaceuticals", which proposed to promote the transformation and upgrading of pharmaceutical circulation enterprises, break the market segmentation of pharmaceutical products, local protection, promote cross-regional and cross-ownership mergers and reorganization of drug distribution enterprises, and cultivate large-scale modern drug circulation backbone enterprises.
to implement the "two-vote system" for drug purchase and sale - the pilot provinces (districts, cities) and public hospital reform pilot cities to take the lead in the implementation of the "two-vote system", to encourage other regions to implement the "two-vote system", and strive to be introduced throughout the country by 2018.
Under the adjustment of the series of policies, on the one hand, the field of domestic drug circulation continues to move towards standardization, on the other hand, it can be said that pharmaceutical circulation enterprises are carrying a heavy burden forward, it is worth noting that the pharmaceutical circulation enterprises mentioned here include both wholesale enterprises, but also retail enterprises, chain pharmacies, monosome pharmacies and so on.
In the process of concentration and standardization of the pharmaceutical circulation industry, experts said that in the past, many pharmaceutical circulation enterprises continue to expand, through investment and mergers and other means to complete the network layout, to achieve scale growth, or through the design of relevant pharmaceutical solutions, to complete market share, the future, the development direction of pharmaceutical circulation enterprises is innovation and transformation.
the profitability of pharmaceutical circulation enterprises without scale is very difficult, in the future, mergers and acquisitions reorganization, strong union is still the mainstream of the industry, but in the distribution services, pharmaceutical services, patient services and other areas of innovation is becoming more and more important.
industry said at the end that the emergence of internal and external competitors in the pharmaceutical circulation industry is a serious challenge for many enterprises.
enterprises need not only sufficient profits to maintain their own development, but also need to constantly break through themselves to meet new challenges.
2020 is the first year of innovation in domestic pharmaceutical circulation, the next 5 years or will determine the overall circulation market pattern.
in the process of increasing industry concentration, which enterprises will continue to advance, which enterprises will be submerged in the dust of history, still need to wait time to find out.
.